Investor Relations · Brands & Companies
Our companies, segments and consumer brands
The operating subsidiaries and strategic investments organised under Novogenia AG, grouped into business segments, plus the consumer brands built on the Group’s genetic-science platform.
Our companies
The operating companies and strategic investments organised under Novogenia AG.
Novogenia GmbH100%
NovoMedic GmbH70%
305Care GmbH85%
HLN Genetik GmbH85%
Mendelio Srl70%
Medicopharm AG100%
INOPHA GmbH51%
ChiruTec GmbH51%
REVIV
Spot Health Inc.
GenomeLink
Nephrogen Inc.Business segments & companies
Our operating divisions, the companies within them and the revenue growth of each segment.
DIAGNOSTICS AND PERSONALIZED PRODUCTS
€52M Cash ReservesGenetic and blood laboratory testing, DNA diagnostics and personalized supplements and cosmetics — the operational core of the Group, fully integrated from sample to finished product.
Novogenia GmbHLaboratory, Supplements & Cosmetics
The operational heart of the Group: an accredited high-throughput genetic and blood laboratory in Salzburg combined with in-house manufacturing of personalized dietary supplements and cosmetics.
novogenia.comNovoMedic GmbHSales to doctors
Distributes Novogenia’s genetic analyses and personalized health products to physicians and medical practices.
novomedic.comGGENius GmbHSales to pharmacies
The pharmacy channel of the Group, bringing genetic testing and personalized supplements to consumers through pharmacy partners.
305Care GmbHB2C cosmetics sales
Direct-to-consumer sales of personalized cosmetics and skincare developed from genetic and skin-analysis data.
305care.comHLN Genetik GmbHClinical laboratory
Clinical genetic laboratory services, extending the Group’s diagnostic capacity into regulated medical testing.
hln-genetik.atMendelio GmbHSoftware development
Builds the software, bioinformatics and AI platforms that interpret genetic data and power the Group’s reports, customer apps and laboratory automation.
mendelio.comCore revenue = Novogenia GmbH organic business excluding COVID-PCR testing.
DRUG IMPORT AND MEDICAL DEVICES
Import and distribution of pharmaceuticals and medical devices to pharmacies, doctors and consumers across Europe.
Medicopharm GmbHPharmaceutical import
Import and wholesale distribution of pharmaceuticals, broadening the Group’s reach into the regulated drug-supply market.
medicopharm.atInopha GmbHDrug import & distribution
Specialist importer sourcing and distributing medicinal products for the European market.
inopha.deChiruTec GmbHMedical devices
Supplies medical devices and surgical products, complementing the Group’s diagnostics and pharmaceutical activities.
chirutec.comPharma Trade was established with the acquisition of Inopha GmbH and ChiruTec GmbH on 29 June 2023 (2022 = 0; 2023 = second half-year only). 2024 is the first full year for both companies; 2025 grew through the full consolidation of Medicopharm AG from 1 January 2025.
MINORITY INVESTMENTS
€10.6M investedStrategic minority stakes across health-tech and life sciences — around €10.6M invested in companies that extend the Group’s reach in consumer genetics, regenerative medicine and bioinformatics.
GGenePlanetConsumer genetics · €2.7M
A leading European consumer-genetics and preventive-health brand, expanding the Group’s direct-to-consumer testing footprint.
geneplanet.comREVIVIV-therapy clinics · €5.9M
A global IV-therapy and wellness clinic network, opening a clinical channel for personalized nutrition and longevity treatments.
revivme.comNephrogenGene therapy · €0.2M
An early-stage gene-therapy venture targeting kidney disease — a strategic foothold in advanced therapeutics.
nephrogenbiotech.comGenomeLinkDNA app platform · €1M
A consumer DNA-app platform delivering ongoing genetic insights from uploaded raw data, reinforcing the Group’s software reach.
genomelink.ioSpot HealthDigital health · €0.8M
A digital-health investment broadening the Group’s exposure to connected, app-based preventive care.
spotdx.comOur brands
Consumer brands built on the Group’s genetic-science platform.
Genopedia
An accessible knowledge platform that translates the latest genetic science into clear, actionable insights — Novogenia’s encyclopedia of human genetics, connecting every analysis to the research behind it.
Personalized daily supplementsNovoDaily
A personalized daily-supplement subscription: each sachet is formulated from the customer’s own genetic and lifestyle data and produced in-house — the right nutrients, in the right dose, every day.
Investor & press contact
Questions from shareholders, analysts or media? Our Investor Relations team is happy to help.